A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Clinical trial NCT04442022 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04442022
- Sponsor
- Karyopharm Therapeutics Inc
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-03
- Primary completion
- 2026-12-01
- Enrollment
- 501
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.